| typ : |
Czasopismo |
| link internetowy : |
http://www.ijpc.com/Abstracts/Abstract.cfm?ABS=284 |
|
| Zespoły badawcze : |
Houston - M.D.Anderson Cancer Center |
| Autorzy : |
Zhang YP, Trissel LA, Fox JL. |
| Tytuł : |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions. |
| Numer : |
Int J Pharm Compound ; 4: 69-71. 2000 |
|
| Poziom wiarygodności : |
|
| stabilność fizyczną : |
|
| Stabilność chemiczna : |
|
| Inne metody : |
|
| Komentarze : |
|
Listy
 Naratriptan Hydrochloride
|
 |
 |
 |
 |
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
23°C |
 |
| 7 |
 |
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
23°C |
|
| 7 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
|
15 mg
Amerge® |
| OraPlus® / OraSweet SF® (1:1) |
>> 30 mL |
|
4°C |
|
| 90 |
|
|
|
|
|
